stella
beta
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma — Stella
Recruiting
Back to Neuroblastoma trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong
View full record on ClinicalTrials.gov